Adenosine A2a Receptor Protein

Adenosine A2a Receptor Protein
Ligand Type	Examples
Antagonists	Istradefylline, Caffeine, SCH58261
Agonists	CGS21680, Regadenoson
Allosteric modulators	VCP746
Brain Region	Expression Level
Striatum (Caudate/Putamen)	Very High
Nucleus Accumbens	High
Olfactory Bulb	High
[Hippocampus](/brain-regions/hippocampus)	Moderate
[Cortex](/brain-regions/cortex)	Low-Moderate
Thalamus	Low
Cerebellum	Low
Pathway Signaling Pathways	Effect
MAPK/ERK	Activation
PI3K/AKT	Activation
[NF-κB](/entities/nf-kb)	Modulation
β-arrestin	Recruitment
Condition	Role
Depression	Anhedonia, motivation
Anxiety	Stress response
Cancer	Immunosuppression
Stroke	Neuroprotection
Huntington's Disease	Motor symptoms
Drug	Approval
Istradefylline (Nourianz)	2019
Compound	Company
Tozadenant	Biotie
Preladenant	Merck
ST1535	Sigma-[Tau](/proteins/tau)
Vipadenant	Vicore
Associated Diseases	ALS, Aging, Alzheimer, neurodegeneration
SciDEX Hypotheses	Adenosine-Astrocyte Metabolic Reset...
KG Connections	65 edges

Introduction

Adenosine A2A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Adenosine A2a receptor (A2AR, ADORA2A) is a Gs protein-coupled receptor that stimulates adenylate cyclase activity, increasing intracellular cAMP levels. A2AR is highly enriched in the striatum (caudate nucleus and putamen) where it plays a critical role in modulating motor control, reward processing, and habit formation. This receptor has emerged as a major therapeutic target for Parkinson’s disease, with the A2AR antagonist istradefylline (Nourianz) FDA-approved as an adjunct therapy. Beyond PD, A2AR modulators are being investigated for Alzheimer’s disease, schizophrenia, depression, and cancer immunotherapy.

Structure and Pharmacology

Receptor Architecture

A2AR is a typical GPCR with seven transmembrane domains:

• N-terminal extracellular domain: Contains glycosylation sites

• Seven transmembrane helices (TM1-TM7): Form the ligand-binding pocket

• Intracellular loops (ICL1-3): Couple to G-proteins

• C-terminal intracellular tail: Contains phosphorylation sites and palmitoylation

Ligand Binding

Structural Features

Key structural elements:

• Conserved DRY motif: Critical for G-protein coupling

• Ball-and-chain intracellular helix 8: Regulates desensitization

• Disulfide bond: Stabilizes extracellular loops

• Glycosylation: N-terminal ASN residues

Expression Pattern

Brain Distribution

A2AR shows highly region-specific expression:

Cellular Localization

• Medium spiny neurons (MSNs): Highest density on D2-expressing MSNs

• Glial cells: Astrocytes and microglia express A2AR

• Endothelial cells: Vascular A2AR regulate blood flow

• Immune cells: T cells, B cells, macrophages

Signaling Mechanisms

Primary Signaling Pathway

A2AR activates Gs/olf proteins leading to:

1. Adenylate cyclase activation → ↑ cAMP

2. Protein kinase A (PKA) activation → Phosphorylation of substrates

3. CREB activation → Gene transcription

4. PKA phosphorylation of DARPP-32 → Modulation of striatal signaling

Secondary

Cross-talk with Dopamine

A2AR-D2R interaction is crucial in striatum:

• Antagonistic relationship: A2AR activation reduces D2R signaling

• Heteromer formation: A2AR-D2R receptor complexes

• Therapeutic implications: A2AR blockade enhances D2R function

Disease Associations

Parkinson’s Disease

A2AR is the primary therapeutic target in PD:

• Mechanism: A2AR overactivity in PD reduces motor function

• Therapeutic strategy: A2AR antagonists restore dopaminergic tone

• Clinical use: Istradefylline as add-on to levodopa

• Benefits: Reduced “off” time, improved “on” time

Alzheimer’s Disease

Emerging evidence for A2AR involvement:

• Neuroinflammation: A2AR on microglia modulates inflammation

• Amyloid pathology: A2AR affects Aβ clearance

• Memory function: Hippocampal A2AR regulates memory

• Therapeutic potential: A2AR modulators in development

Schizophrenia

A2AR dysfunction implicated in schizophrenia:

• Dopamine hypothesis interaction: Striatal A2AR-D2R balance

• Cognitive deficits: Prefrontal A2AR modulation

• Negative symptoms: Possible therapeutic benefit

• Genetic associations: ADORA2A polymorphisms linked to schizophrenia

Other Conditions

Therapeutic Targeting

FDA-Approved Therapies

Clinical Pipeline

Challenges in Drug Development

1. Peripheral vs central effects: Limiting side effects

2. Species differences: Rodent vs human receptor pharmacology

3. Blood-brain barrier penetration: Required for CNS indications

4. Cardiovascular safety: A2AR in heart and vasculature

Animal Models

Knockout Studies

• Adora2a-/- mice: Resistant to A2AR agonist effects

• Conditional KO: Brain-specific deletion

• Humanized mice: Express human A2AR

Phenotypic Findings

• Enhanced D2R signaling

• Reduced parkinsonian symptoms

• Altered reward processing

• Modified inflammatory responses

Disease Models

• 6-OHDA lesions: A2AR antagonists protect

• MPTP toxicity: Modulation of neurodegeneration

• Transgenic models: α-synuclein overexpression

Research Directions

1. Receptor structure: Cryo-EM of A2AR-G protein complexes

2. Heteromer biology: A2AR-D2R and A2AR-A1R complexes

3. Biomarkers: PET ligands for A2AR imaging

4. Immunotherapy: A2AR antagonists in cancer

5. Gene therapy: Viral vector delivery approaches

Background

The study of Adenosine A2A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.